Cargando…

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not been implemented widely. In a European setting, TIL-therapy has been in use since 2011 and is currently being evaluated in a randomized controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindenberg, Melanie A., Retèl, Valesca P., van den Berg, Joost H., Geukes Foppen, Marnix H., Haanen, John B., van Harten, Wim H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200372/ https://www.ncbi.nlm.nih.gov/pubmed/30300260 http://dx.doi.org/10.1097/CJI.0000000000000245

Ejemplares similares

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
por: Rohaan, Maartje W., et al.
Publicado: (2018)

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
por: Lindenberg, Melanie A., et al.
Publicado: (2022)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
por: Verbeek, Joost G. E., et al.
Publicado: (2023)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
por: Retèl, Valesca P, et al.
Publicado: (2011)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2018)

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation
por: van Harten, WH, et al.
Publicado: (2016)

Association between genomic recurrence risk and well-being among breast cancer patients
por: Retèl, Valesca P, et al.
Publicado: (2013)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
por: Deken, Marcel A., et al.
Publicado: (2016)

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
por: Geukes Foppen, Marnix H, et al.
Publicado: (2018)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
por: Verbeek, Joost G. E., et al.
Publicado: (2019)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

The use of advanced medical technologies at home: a systematic review of the literature
por: ten Haken, Ingrid, et al.
Publicado: (2018)

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
por: van Delft, Frederik, et al.
Publicado: (2020)

Barriers and Facilitators Affecting Patient Portal Implementation from an Organizational Perspective: Qualitative Study.
por: Kooij, Laura, et al.
Publicado: (2018)

Reporting incidents involving the use of advanced medical technologies by nurses in home care: a cross-sectional survey and an analysis of registration data
por: ten Haken, Ingrid, et al.
Publicado: (2021)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

Neoantigen Targetability in Progressive Advanced Melanoma
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Health state utility and health-related quality of life measures in patients with advanced ovarian cancer
por: van Stein, Ruby M., et al.
Publicado: (2023)

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care
por: van Not, Olivier J., et al.
Publicado: (2021)

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
por: Rohaan, M.W., et al.
Publicado: (2022)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u5kqh2j931rig95f8330un7ueh